Journal Article
Research Support, Non-U.S. Gov't
Review
Add like
Add dislike
Add to saved papers

Iron oxide nanoparticles for targeted cancer imaging and diagnostics.

Superparamagnetic iron oxide nanoparticles (SPIONs) have proven to be highly effective contrast agents for the magnetic resonance imaging diagnosis of solid tumors. This review examines the various techniques that are available to selectively target SPIONs toward a wide variety of cancerous tissues, with specific attention given to how the surface properties imparted by various targeting ligands affect the particles tissue distribution and pharmacokinetics. An in-depth examination of the various human cell lines utilized to test the assorted targeting methods is also presented, as well as an overview of the various types of cancer against which each targeting method has been utilized for both in vivo and in vitro studies. From the Clinical Editor: Functionalized superparamagnetic iron oxide nanoparticles (SPIONs) are very potent negative contrast materials for magnetic resonance imaging-based diagnosis. This comprehensive review examines techniques that selectively target SPIONs toward a wide variety of malignancies.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app